A study published in Nature Medicine highlights how genetic data can be translated in disease prevention and evidence-based clinical management.
Scientists at the University of Oxford, in collaboration with the gene sequencing company Illumina, have published results in the journal Nature Genetics that underscore how important whole genome sequencing could prove in preventing disease. For about 60% of patients who had participated in the study, whole genome sequencing diagnosed genetic disorders. Standard genetic tests had failed to do so in those patients.
Convinced of the importance of these results, the UK's National Health Service plans to sequence the genomes of 100,000 patients through the Genomics England programme. The results of the study have translated into the discovery of 10 new disease-causing genes for inherited cancers and blood disorders, epilepsy, and conditions affecting the muscles or development. The authors predict the importance of their study in preventive diagnosis and clinical management.
Read the article on MedicalXpress: http://bit.ly/1K5ZZQp
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More